KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2025)

Amneal Pharmaceuticals has reported Receivables over the past 9 years, most recently at $24.6 million for Q4 2025.

  • Quarterly results put Receivables at $24.6 million for Q4 2025, down 96.85% from a year ago — trailing twelve months through Dec 2025 was $24.6 million (down 96.85% YoY), and the annual figure for FY2025 was $24.6 million, down 96.85%.
  • Receivables for Q4 2025 was $24.6 million at Amneal Pharmaceuticals, down from $1.4 billion in the prior quarter.
  • Over the last five years, Receivables for AMRX hit a ceiling of $1.4 billion in Q3 2025 and a floor of $1.9 million in Q1 2024.
  • Median Receivables over the past 5 years was $650.9 million (2021), compared with a mean of $666.7 million.
  • Biggest five-year swings in Receivables: plummeted 99.65% in 2024 and later soared 66290.28% in 2025.
  • Amneal Pharmaceuticals' Receivables stood at $663.8 million in 2021, then plummeted by 95.01% to $33.1 million in 2022, then plummeted by 90.48% to $3.2 million in 2023, then soared by 24636.75% to $780.2 million in 2024, then crashed by 96.85% to $24.6 million in 2025.
  • The last three reported values for Receivables were $24.6 million (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.